Hemp
Legalization to Open New Markets for Digipath
LAS
VEGAS,
NV
-- December
18,
2018
-- InvestorsHub NewsWire -- Digipath,
Inc. (OTCQB:
DIGP), a
service-oriented
independent
testing
laboratory
and
data
firm
focused
on
the
developing
cannabis
and
hemp markets,
is
pleased
to
announce
its
support
of
Congress's Farm Bill, which legalizes the
production and
sale of
hemp.
The
Farm Bill is expected to be signed by the
President shortly,
and will then take immediate effect.
As one
of Nevada's first licensed cannabis testing laboratories,
Digipath has
extensive experience testing hemp over the past two
years. It
is anticipated
that
following the
effectiveness of the Farm
Bill,
demand
for both hemp and the testing
of hemp
will grow significantly.
In
fact, Fortune
magazine, in
a
recent post reacting to
the
Senate's passage of the Farm
Bill, predicted
that
the U.S. cannabis industry could grow to $20 billion by 2022 from
$800 million this year.
"Passage
of
The
Farm Bill
could be enormously beneficial
to our expansion efforts," stated
Todd
Denkin, CEO and Founder,
Digipath, Inc.
"Federal
legalization is expected to
expand
our addressable
market,
and we intend to aggressively pursue a Digipath presence in viable
new markets
that emerge.
With the advent of hemp
legalization ,
it is not just
raw hemp that
will require
testing.
Rather,
all
products containing
hemp and hemp
byproducts
that
are already starting to infiltrate our grocery
and drug store shelves,
such as cosmetics,
creams, tinctures,
and
patches
will
all
need
to be tested before
they
reach consumers.
Digipath
is
able to provide
that testing."
About Digipath, Inc. & Digipath Labs, Inc.
Digipath, Inc. supports
the cannabis industry's best practices for reliable testing, data
acquisition, cannabis education and training, and brings unbiased
cannabis news coverage to the cannabis industry. Digipath
Labs provides
pharmaceutical-grade analysis and testing to the cannabis industry
to ensure producers, consumers, and patients know exactly what is
in the cannabis they ingest and to help maximize the quality of its
client's products through analysis, research, development, and
standardization.
Digipath Investor Relations & Financial Media
info@integrityir.com
Toll
Free: (888) 216-3595
www.IntegrityIR.com
Information
about
Forward-Looking
Statements
This
press
release
contains
"forward-looking
statements"
that
include
information
relating
to
future
events.
Forward-looking
statements
should
not
be
read
as
a
guarantee
of
future
performance
or
results
and
will
not
necessarily
be
accurate
indications
of
the
times
at,
or
by,
which
that
performance
or
those
results
will
be
achieved.
Forward-looking
statements
are
based
on
information
available
at
the
time
they
are
made
and/or
management's
good
faith
belief
as
of
that
time
with
respect
to
future
events
and
are
subject
to
risks
and
uncertainties
that
could
cause
actual
performance
or
results
to
differ
materially
from
those
expressed
in,
or
suggested
by,
the
forward-looking
statements.
Important
factors
that
could
cause
these
differences
include,
but
are
not
limited
to:
the
Company's
need
for
additional
funding,
the
demand
for
the
Company's
products,
governmental
regulation
of
the
cannabis
industry,
the
Company's
ability
to
maintain
customer
and
strategic
business
relationships,
the
impact
of
competitive
products
and
pricing,
growth
in
targeted
markets,
the
adequacy
of
the
Company's
liquidity
and
financial
strength
to
support
its
growth,
and
other
risks
that
may
be
detailed
from
time-to-time
in
the
Company's
filings
with
the
United
States
Securities
and
Exchange
Commission.
For
a
more
detailed
description
of
the
risk
factors
and
uncertainties
affecting
Digipath,
please
refer
to
the
Company's
recent
Securities
and
Exchange
Commission
filings,
which
are
available
at
www.sec.gov.
The
Company
undertakes
no
obligation
to
publicly
update
or
revise
any
forward-looking
statements,
whether
as
a
result
of
new
information,
future
events,
or
otherwise.